Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: Impact on extracellular matrix

Journal of Sexual Medicine

Volumn 7, Issue 6, 2010, Pages 2077-2085

  Shindel, Alan W ^a   Lin, Guiting ^a   Ning, Hongxiu ^a   Banie, Lia ^a   Huang, Yun Ching ^a   Liu, Gang ^a   Lin, Ching Shwun ^a   Lue, Tom F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Elastin; Fibroblasts; Pentoxifylline; Peyronie's Disease; TGF Beta; Tunica Albuginea

Indexed keywords

COLLAGEN TYPE 1; ELASTIN; PENTOXIFYLLINE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL PROLIFERATION; COLLAGEN METABOLISM; CONCENTRATION RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PEYRONIE DISEASE; PHENOTYPE; PRIORITY JOURNAL; TUNICA ALBUGINEA; UPREGULATION;

EID: 77953928704     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01790.x     Document Type: Article

References (36)

1. Iacono F, Barra S, De Rosa G, Boscaino A, Lotti T. Microstructural disorders of tunica albuginea in patients affected by Peyronie's disease with or without erection dysfunction. J Urol 1993, 150:1806-9.
2. Bella AJ, Perelman MA, Brant WO, Lue TF. Peyronie's disease (CME). J Sex Med 2007, 4:1527-38.
3. Gonzalez-Cadavid NF. Mechanisms of penile fibrosis. J Sex Med 2009, 6(3):353-62. suppl
4. De Young LX, Bella AJ, O'Gorman DB, Gan BS, Lim KB, Brock GB. Protein biomarker analysis of primary Peyronie's disease cells. J Sex Med 2010, 7:99-106.
5. Pohlers D, Brenmoehl J, Loffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G. TGF-beta and fibrosis in different organs-molecular pathway imprints. Biochim Biophys Acta 2009, 1792:746-56.
6. El-Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya R, Lue TF. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. J Urol 1997, 158:2284-90.
7. El-Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. J Urol 1997, 158:1391-4.
8. Moreland RB, Traish A, McMillin MA, Smith B, Goldstein I, Saenz de Tejada I. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995, 153:826-34.
9. Cutroneo KRTG. F-beta-induced fibrosis and SMAD signaling: Oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 2007, 15(1):S54-60. suppl
10. Kuang PP, Zhang XH, Rich CB, Foster JA, Subramanian M, Goldstein RH. Activation of elastin transcription by transforming growth factor-beta in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2007, 292:L944-52.
11. Wagenseil JE, Mecham RP. New insights into elastic fiber assembly. Birth Defects Res C Embryo Today 2007, 81:229-40.
12. Stewart S, Malto M, Sandberg L, Colburn KK. Increased serum levels of anti-elastin antibodies in patients with Peyronie's disease. J Urol 1994, 152:105-6.
13. Akkus E, Carrier S, Baba K, Hsu GL, Padma-Nathan H, Nunes L, Lue TF. Structural alterations in the tunica albuginea of the penis: Impact of Peyronie's disease, ageing and impotence. Br J Urol 1997, 79:47-53.
14. Deree J, Martins J, de Campos T, Putnam JG, Loomis WH, Wolf P, Coimbra R. Pentoxifylline attenuates lung injury and modulates transcription factor activity in hemorrhagic shock. J Surg Res 2007, 143:99-108.
15. Hung KY, Huang JW, Chiang CK, Tsai TJ. Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: Molecular studies. Nephrol Dial Transplant 2008, 23:3831-40.
16. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005, 16:2702-13.
17. Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC, Lan HY. Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol 2009, 29:43-53.
18. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. l-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229-44.
19. Brant WO, Dean RC, Lue TF. Treatment of Peyronie's disease with oral pentoxyfylline. Nat Clin Pract Urol 2006, 3:111-5.
20. Lin GT, Wang Z, Liu BC, Lue TF, Lin CS. Identification of potential biomarkers of Peyronie's disease. Asian J Androl 2005, 7:237-43.
21. Mulhall JP, Nicholson B, Pierpaoli S, Lubrano T, Shankey TV. Chromosomal instability is demonstrated by fibroblasts derived from the tunica of men with Peyronie's disease. Int J Impot Res 2004, 16:288-93.
22. Lin G, Chow S, Lin J, Wang G, Lue TF, Lin CS. Effect of cell passage and density on protein kinase G expression and activation in vascular smooth muscle cells. J Cell Biochem 2004, 92:104-12.
23. ten Dijke P, Hill CS. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29:265-73.
24. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-84.
25. Hirai M, Horiguchi M, Ohbayashi T, Kita T, Chien KR, Nakamura T Latent TG. F-beta-binding protein 2 binds to DANCE/fibulin-5 and regulates elastic fiber assembly. EMBO J 2007, 26:3283-95.
26. Hassoba H, El-Sakka A, Lue T. Role of increased transforming growth factor beta protein expression in the pathogenesis of Peyronie's disease. Egypt J Immunol 2005, 12:1-8.
27. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000, 163:1992-8.
28. Mulhall JP, Anderson MS, Lubrano T, Shankey TV. Peyronie's disease cell culture models: Phenotypic, genotypic and functional analyses. Int J Impot Res 2002, 14:397-405.
29. Del Carlo M, Cole AA, Levine LA. Differential calcium independent regulation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by interleukin-1beta and transforming growth factor-beta in Peyronie's plaque fibroblasts. J Urol 2008, 179:2447-55.
30. Szardening-Kirchner C, Konrad L, Hauck EW, Haag SM, Eickelberg O, Weidner W. Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease. World J Urol 2009, 27:123-30.
31. Hoff CR, Perkins DR, Davidson JM. Elastin gene expression is upregulated during pulmonary fibrosis. Connect Tissue Res 1999, 40:145-53.
32. Cantor JO, Keller S, Mandl I, Turino GM. Increased synthesis of elastin in amiodarone-induced pulmonary fibrosis. J Lab Clin Med 1987, 109:480-5.
33. Costa WS, Rebello SB, Cardoso LE, Cavalcanti AG, Sampaio FJ. Stereological and biochemical analysis of muscular and connective tissue components in the penile corpus cavernosum adjacent to the fibrous plaque of Peyronie's disease. BJU Int 2009, 103:212-6.
34. Gonzalez-Cadavid NF, Rajfer J. Experimental models of Peyronie's disease. Implications for new therapies. J Sex Med 2009, 6:303-13.
35. Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985, 37:25-8.
36. Nicklasson M, Bjorkman S, Roth B, Jonsson M, Hoglund P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality 2002, 14:643-52.